Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis

Molecular Neurobiology

Volumn 53, Issue 1, 2016, Pages 720-727

  Han, Mingzhi ^a,d   Guo, Laixiu ^b   Zhang, Ya ^c,d   Huang, Bin ^a   Chen, Anjing ^a   Chen, Weiliang ^a   Liu, Xupeng ^d   Sun, Shicheng ^d   Wang, Kun ^d   Liu, Ao ^d   Li, Xingang ^a  

^a SHANDONG UNIVERSITY   (China)

^b JINING NO 1 PEOPLE S HOSPITAL   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

CD133; Gliomas; Meta analysis; Prognosis; WHO grade

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN; TUMOR MARKER;

AGE; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER STEM CELL; GENDER; GLIOMA; HEALTH CARE ORGANIZATION; HUMAN; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; BIOSYNTHESIS; BRAIN NEOPLASMS; META ANALYSIS; METABOLISM;

AC133 ANTIGEN; ANTIGENS, CD; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; GLIOMA; GLYCOPROTEINS; HUMANS; PEPTIDES; PROGNOSIS;

EID: 84953352572     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-9018-9     Document Type: Article

References (36)

1. Cheng Y, Zhao J, Qiao W, Chen K (2014) Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. Am J Nucl Med Mol Imaging 4(5):385–405
2. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507
3. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells: perspectives on current status and future directions—AACR workshop on cancer stem cells. Cancer Res 66(19):9339–9344
4. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, Cao B, Liu C, Wu G, Ao H, Zhang X, Jiang J (2013) Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci 110(17):6829–6834
5. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68(23):9703–9711
6. O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110
7. Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99(8):1285–1289
8. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62(8):1212–1218
9. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, Ikemoto T (2010) CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45(8):896–902
10. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14(1):123–129
11. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J (2008) Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 27:85
12. Dahlrot RH, Hansen S, Jensen SS, Schrøder HD, Hjelmborg J, Kristensen BW (2014) Clinical value of CD133 and nestin in patients with glioma: a population-based study. Int J Clin Exp Pathol 7(7):3739–3751
13. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18(4):705–719
14. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1):16
15. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834
16. Sterne JA, Egger M (2001) Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. J Clin Epidemiol 54(10):1046–1055
17. Li SZ, Huang W, Yang LT, Yu YJ, Huang GX, Huang CJ (2014) Expression of CD133, SSEA 1 and Nestin in human gliomas and its significance. Chin J Minim Invasive Neurosurg 19(7):327–330
18. Shin JH, Lee YS, Hong YK, Kang CS (2013) Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. J Neurooncol 115(3):333–341
19. Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C, Tominaga T (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol 15(9):1151–1159
20. Xing PH, Lv ZQ, Zhang XX, Liu HY, Tong J, Liu YZ, Zhang L, Yuan JW (2013) Study on correlations among the expression of HIF-1, MGMT and CD133 in human glioblastoma. Chin J Nerv Ment Dis 39(9):523–527
21. Pan L, Kong LJ, Sun JN, Liang CH (2013) Relationship between expression of CD133 in glioma tissue and vascular formation. Harbin Med J 33(5):337–338
22. Zhu ZW (2013) The expression and clinical significance of CD133 and CDl66 in gliomas. South Med Univ 1(1):18–21
23. Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A (2012) MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med 10:250
24. Kong LJ, Jiao BH, Zhang AJ, Cui GS, Sun JN, Li FM, Li SB (2012) Expressions and distribution characteristics of CD133 and nestin positive cells in glioma. Mod Oncol 20(9):1820–1824
25. Ma Q (2012) Expression and clinical significance of MMP-9 and CDl33 protein in human gliomas. Jinan Univ 1(1):8–12
26. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R, Larocca LM (2011) Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer 117(1):162–174
27. Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D (2011) Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol 18(10):2937–2945
28. Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S, Lee MC (2011) The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 31(5):494–502
29. He J, Shan Z, Li L, Liu F, Liu Z, Song M, Zhu H (2011) Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. Oncol Rep 26(5):1305–1313
30. Ke J, Hu XM, Zhou SY, He J, Zhu HQ (2011) Distribution of tumor stem cell and the relationship with p53 and MGMT in glioma. J Mod Oncol 19(7):1322–1324
31. Guo CY, Jiao BH, Liang ZH, Lu SK (2011) The significance of immunohistochemical double staining of CD133/PCNA and Nestin/PCNA coexpression in the basic and clinical glioma research. J Hebei Med Univ 32(7):774–777
32. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB (2010) Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol 96(3):359–367
33. Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X (2008) Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS One 3(4):e1936
34. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R (2008) Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14(24):8205–8212
35. Irollo E, Pirozzi G (2013) CD133: to be or not to be, is this the real question? Am J Transl Res 5(6):563–581
36. Begg CB, Berlin JA (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc A 81(2):107–115